Taking together, YCHT restrains NAFLD progression via upregulating the expression of NR1H4 and APOA1 to modulate lipid metabolism mainly through the cholesterol pathway. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.